NeoGenomics (NASDAQ:NEO) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. The brokerage currently has a $21.00 price target on the medical research company’s stock. Other equities research analysts also recently issued research reports about the company. StockNews.com […]

Related Keywords

United States ,Aliciac Olivo ,Piper Sandler ,Goldman Sachs Group ,Needham Company ,Clinical Services ,Morgan Stanley ,Tower Research Capital ,Neogenomics Company Profile ,Securities Exchange Commission ,Bluepath Capital Management ,Neogenomics Inc ,Highmark Wealth Management ,Pharma Services ,Coppell Advisory Solutions ,Free Report ,Moderate Buy ,Get Free Report ,General Counsel Alicia ,Exchange Commission ,Path Capital Management ,Advisory Solutions ,Financial Advisors ,Research Capital ,Mark Wealth Management ,Neogenomics Daily ,Neogenomics ,Nasdaq Neo ,Neo ,Medical ,Reiterated Rating ,Needham Amp Company Llc ,